Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Armo scooped up by Lilly for $1.5bn

Executive Summary

Eli Lilly & Co. will pay $50 per share (a 79% premium) or approximately $1.5bn to acquire immuno-oncology firm Armo BioSciences Inc. The deal provides a swift exit for Armo shareholders, as the company just went public through a $17 per share/$137mm initial public offering in January of this year.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Intra-Biotech Deal
    • Payment Includes Cash

Related Companies